. . . . . "S&T TWOC Project - version 4" . "S&T TWOC version 3" . "2"^^ . "2023-07-20T09:47:13.868775"^^ . . . "for COVID-19 therapy" . "(226, 238)" . "considered" . "498" . "other antibiotics like azithromycin , ivermectin , eravacycline , valrubicin , streptomycin , nitazoxanide , teicoplanin , caspofungin , and colistin ; and other agents like hydroxychloroquine , chloroquine , tocilizumab , camostat , nafamostat , carfilzomib , interferon , aprepitant , and dexamethasone" . "(226, 238)" . "Results Repurposing of drugs from different pharmacological groups including antivirals like remdesivir, lopinavir, ritonavir, arbidol, oseltamivir, penciclovir, favipiravir, ganciclovir, and ribavirin; other antibiotics like azithromycin, ivermectin, eravacycline, valrubicin, streptomycin, nitazoxanide, teicoplanin, caspofungin, and colistin; and other agents like hydroxychloroquine, chloroquine, tocilizumab, camostat, nafamostat, carfilzomib, interferon, aprepitant, and dexamethasone can be considered for COVID-19 therapy." . "8j41d0a3" . "8j41d0a3-TRIPLE-ABSTRACT-2" . "azithromycin" . "therapy" . "RSA" . "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" . "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" . . .